14C | Unchanged DBP | MBP | MBP-Gluc | |
---|---|---|---|---|
i.v. | ||||
AUC0–inf(i.v.) in plasma4-a | 1.82 ± 0.06 | 0.026 ± 0.003 | 0.28 ± 0.03 | 0.40 ± 0.03 |
Urine | 85.2 ± 2.9 | 25.7 ± 2.5 | 33.5 ± 2.5 | |
Percutaneous | ||||
Cp24h (% dose/ml) | 0.011 ± 0.002 | 0.00006 ± 0.0000 | 0.0045 ± 0.0007 | 0.0045 ± 0.0009 |
du/dt24–48h (% dose/h) | 0.88 ± 0.05 | 0.24 ± 0.02 | 0.38 ± 0.027 (n = 5) | |
From plasma results | ||||
Absorption flux (μg/cm2/h) | 60 ± 12 | 23 ± 34-150 | 161 ± 374-150 | 113 ± 344-150 |
From urinary results | ||||
Absorption flux (μg/cm2/h) | 103 ± 7 | 93 ± 12 | 113 ± 12 |
Values are expressed as mean ± S.E.M. (n = 5).
Cp24h(percut), concentration in plasma of 14C, unchanged DBP, or its two main metabolites after 24 h of a topical application of neat [14C]DBP (10 μl/cm2, 10 cm2). % Q 0, percentage of the administered dose (i.v.) or the applied dose (percutaneous).
↵4-150 Significant difference from the value determined with14C plasma level (p < 0.05).
↵4-a AUC0–inf(i.v.), area under the plasma time curve of 14C, unchanged DBP, or its two main metabolites after a single i.v. administration of [14C]DBP 1 mg/kg in haired male rats (Table 2).